AI Revolutionizes Drug Trials: QuantHealth Secures $45M to Predict Success
August 7, 2026, 9:33 am
Location: Israel, Tel Aviv District, Herzliya
Employees: 11-50
Founded date: 1993
QuantHealth raises $45M in Series B funding. Its AI platform simulates clinical trials. This drastically cuts drug development costs and failure rates. The technology boasts 90% predictive accuracy. It optimizes trial designs for major pharmaceutical companies. Funds will expand AI models, therapeutic indications, and market reach. The move signals a shift towards predictive, data-driven drug innovation. This transformation aims to accelerate therapy delivery.
Drug development is a high-stakes gamble. The statistics are stark. Over 90% of all experimental drugs entering clinical trials fail. Most failures—roughly three out of four—stem from issues with efficacy or safety. This process drains billions. It consumes years. Pharmaceutical companies face immense pressure. They must innovate faster. They must reduce risk.
A paradigm shift is underway. Israeli startup QuantHealth leads this change. The company recently secured $45 million in Series B funding. This brings its total capital raised to $75 million. The investment round was led by Qumra Capital. Key participants included Sanofi Ventures, Pitango HealthTech, Bertelsmann Healthcare Investments, and Accenture Ventures. Artofin, GC Ventures, NewHealth, Shoni Top, and Esplanade Ventures also contributed. This capital infusion fuels an ambitious mission. QuantHealth aims to transform how new medicines reach patients.
The traditional method for drug development is inefficient. Pharma companies design a trial. They enroll patients. Then they wait. Months or even years pass. Data slowly emerges. Only then do they discover if a drug works. Or if it is safe. This trial-and-error approach is slow. It is expensive. It is unforgiving. Costs continue to soar. Competition intensifies. The industry desperately needs a better way.
QuantHealth provides that better way. The company built an advanced AI platform. This platform allows drugmakers to run thousands of simulated clinical trials. They do this *before* enrolling a single patient. Instead of relying on historical benchmarks, the platform models trial outcomes. It predicts how a specific trial design will perform.
The technology offers crucial insights. It tests various protocols. It identifies potential risks for efficacy and safety. Teams can then optimize their strategies. They refine inclusion and exclusion criteria. They model commercial outcomes. This happens long before committing significant capital. This predictive capability is a game-changer. It helps companies fail faster when necessary. It helps them succeed more often.
The platform's accuracy is impressive. QuantHealth reports up to 90% predictive accuracy. This covers over 600 simulated clinical trials. These simulations span more than 30 medical indications. This strong performance has garnered significant industry adoption. Twelve of the world's top twenty pharmaceutical companies now use QuantHealth's technology. They leverage it to design trials. They use it to mitigate development risks.
The new capital will accelerate QuantHealth’s strategic initiatives. First, the company will enhance its AI models. It will develop next-generation AI. It will expand its proprietary datasets. This ensures simulations become even sharper. Greater data leads to greater accuracy.
Second, QuantHealth plans broader therapeutic coverage. It will expand from 30 to over 40 indications. The focus areas include oncology, cardiometabolic, and inflammatory diseases. These are complex and high-cost areas of research. Predictive tools here offer immense value.
Third, the platform will expand its capabilities. It moves beyond just trial design. It will cover the full drug lifecycle. This includes commercial planning. The platform will support drug development from lab to launch. This holistic approach maximizes its impact.
The company will also grow its team. QuantHealth currently employs about 85 people. They are based in Tel Aviv and New York. Expansion means more talent. More talent means faster innovation.
QuantHealth was founded in 2020. Orr Inbar serves as CEO. Arnon Horev is the co-founder. Both observed the challenges in pharma. They saw billion-dollar decisions made with insufficient data. Their vision was clear: empower pharma with predictive power. Early backers recognized this potential. Sanofi and Accenture Ventures were among them. The latest round brings more strategic investors. This strengthens industry trust. Trust is paramount for adoption in healthcare technology.
Clinical trials represent the most expensive and uncertain phase of drug development. The ability to predict failure in simulation saves years. It saves billions. The broader trend is evident. Pharmaceutical development is shifting. It moves from "try it and see" to "predict it first." Predictive technologies are no longer optional. They are becoming core infrastructure.
If QuantHealth's 90% accuracy holds at scale, the implications are vast. Fewer late-stage trial failures become possible. Development timelines will shorten. More effective therapies could reach patients faster. The number of "shots on goal" for new treatments will increase. This means more chances for life-saving drugs.
The path ahead involves challenges. As with any AI in healthcare, validation is key. QuantHealth must prove its simulations consistently match real-world outcomes. This must hold true across diverse diseases. It must apply to various patient populations. It must meet different regulatory requirements. This next phase of development will focus on robust scientific validation. With $45 million, QuantHealth is poised to tackle these challenges. It is betting on a future where AI guides every step of drug development. This promises a healthier future for all.
Drug development is a high-stakes gamble. The statistics are stark. Over 90% of all experimental drugs entering clinical trials fail. Most failures—roughly three out of four—stem from issues with efficacy or safety. This process drains billions. It consumes years. Pharmaceutical companies face immense pressure. They must innovate faster. They must reduce risk.
A paradigm shift is underway. Israeli startup QuantHealth leads this change. The company recently secured $45 million in Series B funding. This brings its total capital raised to $75 million. The investment round was led by Qumra Capital. Key participants included Sanofi Ventures, Pitango HealthTech, Bertelsmann Healthcare Investments, and Accenture Ventures. Artofin, GC Ventures, NewHealth, Shoni Top, and Esplanade Ventures also contributed. This capital infusion fuels an ambitious mission. QuantHealth aims to transform how new medicines reach patients.
The traditional method for drug development is inefficient. Pharma companies design a trial. They enroll patients. Then they wait. Months or even years pass. Data slowly emerges. Only then do they discover if a drug works. Or if it is safe. This trial-and-error approach is slow. It is expensive. It is unforgiving. Costs continue to soar. Competition intensifies. The industry desperately needs a better way.
QuantHealth provides that better way. The company built an advanced AI platform. This platform allows drugmakers to run thousands of simulated clinical trials. They do this *before* enrolling a single patient. Instead of relying on historical benchmarks, the platform models trial outcomes. It predicts how a specific trial design will perform.
The technology offers crucial insights. It tests various protocols. It identifies potential risks for efficacy and safety. Teams can then optimize their strategies. They refine inclusion and exclusion criteria. They model commercial outcomes. This happens long before committing significant capital. This predictive capability is a game-changer. It helps companies fail faster when necessary. It helps them succeed more often.
The platform's accuracy is impressive. QuantHealth reports up to 90% predictive accuracy. This covers over 600 simulated clinical trials. These simulations span more than 30 medical indications. This strong performance has garnered significant industry adoption. Twelve of the world's top twenty pharmaceutical companies now use QuantHealth's technology. They leverage it to design trials. They use it to mitigate development risks.
The new capital will accelerate QuantHealth’s strategic initiatives. First, the company will enhance its AI models. It will develop next-generation AI. It will expand its proprietary datasets. This ensures simulations become even sharper. Greater data leads to greater accuracy.
Second, QuantHealth plans broader therapeutic coverage. It will expand from 30 to over 40 indications. The focus areas include oncology, cardiometabolic, and inflammatory diseases. These are complex and high-cost areas of research. Predictive tools here offer immense value.
Third, the platform will expand its capabilities. It moves beyond just trial design. It will cover the full drug lifecycle. This includes commercial planning. The platform will support drug development from lab to launch. This holistic approach maximizes its impact.
The company will also grow its team. QuantHealth currently employs about 85 people. They are based in Tel Aviv and New York. Expansion means more talent. More talent means faster innovation.
QuantHealth was founded in 2020. Orr Inbar serves as CEO. Arnon Horev is the co-founder. Both observed the challenges in pharma. They saw billion-dollar decisions made with insufficient data. Their vision was clear: empower pharma with predictive power. Early backers recognized this potential. Sanofi and Accenture Ventures were among them. The latest round brings more strategic investors. This strengthens industry trust. Trust is paramount for adoption in healthcare technology.
Clinical trials represent the most expensive and uncertain phase of drug development. The ability to predict failure in simulation saves years. It saves billions. The broader trend is evident. Pharmaceutical development is shifting. It moves from "try it and see" to "predict it first." Predictive technologies are no longer optional. They are becoming core infrastructure.
If QuantHealth's 90% accuracy holds at scale, the implications are vast. Fewer late-stage trial failures become possible. Development timelines will shorten. More effective therapies could reach patients faster. The number of "shots on goal" for new treatments will increase. This means more chances for life-saving drugs.
The path ahead involves challenges. As with any AI in healthcare, validation is key. QuantHealth must prove its simulations consistently match real-world outcomes. This must hold true across diverse diseases. It must apply to various patient populations. It must meet different regulatory requirements. This next phase of development will focus on robust scientific validation. With $45 million, QuantHealth is poised to tackle these challenges. It is betting on a future where AI guides every step of drug development. This promises a healthier future for all.